CLRB — Cellectar Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $19.04m
- $5.14m
Annual cashflow statement for Cellectar Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -15.1 | -24.1 | -28.6 | -38 | -44.6 |
| Depreciation | |||||
| Non-Cash Items | 0.349 | 1.2 | 1.55 | 1.94 | -1.57 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.671 | 0.199 | 1.68 | 3.48 | -1.73 |
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -13.9 | -22.6 | -25.2 | -32.4 | -47.6 |
| Capital Expenditures | -0.062 | -0.141 | -0.226 | -0.864 | -0.104 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.062 | -0.141 | -0.226 | -0.864 | -0.104 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 60.5 | 1.25 | 9.61 | 22.9 | 61.4 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 46.6 | -21.5 | -15.8 | -10.3 | 13.7 |